论文部分内容阅读
Abbott公司的克拉霉素缓释片 (商品名 Biaxin RXL)新的 7d适应症获得美国食品与药品管理局(FDA)批准用于治疗成人轻至中度社区获得性肺炎。申报资料中的研究显示 ,该克拉霉素缓释片的临床治愈率与喹诺酮类的主要品种左氧氟沙星的临床治愈率相当。FDA批准克拉霉素缓释片用于社区
Abbott’s Clarithromycin Sustained-release Tablet (Biaxin RXL) New 7d indication is approved by the U.S. Food and Drug Administration for the treatment of mild-to-moderate community-acquired pneumonia in adults. The application data in the study showed that the clarithromycin sustained-release tablets clinical cure rate and the main quinolone levofloxacin clinical cure rate is quite. FDA approves clarithromycin sustained-release tablets for use in the community